Compugen, Inc.
Compugen, Inc., a leading biotechnology company headquartered in California, has been at the forefront of immuno-oncology since its establishment in 1998. With a strong presence in North America and Israel, Compugen focuses on the discovery and development of novel therapeutic agents that harness the immune system to combat cancer. The company is renowned for its innovative approach to drug development, particularly its unique computational biology platform that identifies new immune checkpoints and therapeutic targets. Compugen's core products include monoclonal antibodies and immune-modulating therapies, which have shown promise in clinical trials. Recognised for its significant contributions to the field, Compugen has achieved notable milestones, including strategic partnerships with major pharmaceutical companies, solidifying its position as a key player in the biotechnology industry.
DitchCarbon Score
How does Compugen, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Financial Intermediation industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Compugen, Inc.'s score of 27 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Compugen, Inc.'s reported carbon emissions
In 2022, Compugen, Inc., headquartered in California, reported significant carbon emissions, with a total of approximately 13,567,000 kg CO2e attributed to Scope 3 emissions. Notably, the company recorded no emissions in Scope 1 and Scope 2 categories, indicating a potential focus on indirect emissions from its value chain. Despite the absence of specific reduction targets or initiatives, Compugen's commitment to addressing climate change is evident through its transparency in emissions reporting. The company has not established formal reduction targets under the Science Based Targets initiative (SBTi) or other climate pledges, which may suggest an opportunity for future commitments in line with industry standards. Overall, Compugen's emissions profile highlights the importance of addressing Scope 3 emissions, which often represent the largest share of a company's carbon footprint. As the company continues to navigate its climate commitments, stakeholders may look for further developments in its sustainability strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | - |
| Scope 2 | - |
| Scope 3 | 13,567,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Compugen, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
